Ozempic increased by 3.5% to nearly $970 for a month’s supply, and Mounjaro grew 4.5% to nearly $1,070 a month, according to data from 46brooklyn Research. The research organization has also noted an odd trend in 2024: Drug price deductions are canceling out the increases.
Novo Nordisk, the maker of Ozempic, told the outlet that market conditions and inflation affect list prices, and Mounjaro-maker Eli Lilly said its medication prices are based on value, efficacy and safety.
Both medications are in a popular class of drugs called GLP-1s, or glucagon-like peptide-1 receptor agonists.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
